Misinformation about which drugs worked and which did not at the outset of the pandemic complicated the lives of compliance chiefs at Pfizer and Regeneron Pharmaceuticals Inc. Both Rady Johnson of Pfizer and Beth Holly of Regeneron said their companies made the decision to be completely, even overly, transparent when developing a vaccine and drug to combat COVID-19.
April 14, 2021 at 04:53 PM
1 minute read
At the beginning of the COVID-19 pandemic, Rady Johnson and Beth Holly knew their companies needed to be transparent when creating and rolling out treatments for the never-before-seen virus.
From the outset of the pandemic, Johnson, the chief compliance, quality and risk officer at Pfizer in New York, and Holly, the chief compliance officer at Regeneron Pharmaceuticals Inc. in Tarrytown, New York, acknowledged public skepticism of the pharmaceutical industry.
Presented by BigVoodoo
General Counsel Summit is the premier event for in-house counsel, hosting esteemed legal minds from all sectors of the economy.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
WIPL is the original global forum facilitating women-to-women exchange on leadership and legal issues.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Predictive reporting, trend analysis, peer guidance and a practical playbook to help genetal counsels succeed in their increasingly high stakes roles as risk managers and corporate strategists
(Left to right): Rady Johnson, executive vice president, chief compliance, quality and risk officer at Pfizer, and Beth Holly, senior vice president, chief compliance officer at Regeneron Pharmaceuticals Inc. Courtesy photo
